1.
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiologica...
by Yusuf, Salim, Prof
The Lancet (British edition), 2011, Vol.378 (9798), p.1231-1243
2.
Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis
by Lindholm, Lars Hjalmar
The Lancet (British edition), 2005, Vol.366 (9496), p.1545-1553
3.
Atenolol in hypertension: is it a wise choice?
by Carlberg, Bo
The Lancet (British edition), 2004, Vol.364 (9446), p.1684-1689
5.
Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study da...
by Khatib, Rasha, PhD
The Lancet (British edition), 2016, Vol.387 (10013), p.61-69
6.
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial
by Devereaux, P J
The Lancet (British edition), 2008, Vol.371 (9627), p.1839-1847
7.
Hospitalizations for New Heart Failure Among Subjects With Diabetes Mellitus in the RENAAL and LIFE Studies
by Carr, Albert A
The American journal of cardiology, 2005, Vol.96 (11), p.1530-1536
8.
Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis
by Kotecha, Dipak, Dr
The Lancet (British edition), 2014, Vol.384 (9961), p.2235-2243
9.
Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: Experiences from MERIT-HF
by Deedwania, Prakash C
The American heart journal, 2005, Vol.149 (1), p.159-167
10.
Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET
by Torp-Pedersen, Christian
The American heart journal, 2005, Vol.149 (2), p.370-376
11.
Infantile haemangioma
by Léauté-Labrèze, Christine, Dr
The Lancet (British edition), 2017, Vol.390 (10089), p.85-94
12.
Dilated cardiomyopathy
by Weintraub, Robert G, Dr
The Lancet (British edition), 2017, Vol.390 (10092), p.400-414
13.
Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol
by Reiberger, Thomas
Gut, 2013-11, Vol.62 (11), p.1634-1641
14.
Heart failure
by Metra, Marco, MD
The Lancet (British edition), 2017, Vol.390 (10106), p.1981-1995
15.
Hyperthyroidism
by De Leo, Simone, MD
The Lancet (British edition), 2016, Vol.388 (10047), p.906-918
16.
Reexamining the Effect of Antihypertensive Medications on Falls in Old Age
by Lipsitz, Lewis A
Hypertension (Dallas, Tex. 1979), 2015-07, Vol.66 (1), p.183-189
17.
A Randomized Trial of Brimonidine Versus Timolol in Preserving Visual Function: Results From the Low-pressure Glaucoma Treatment Study
by Krupin, Theodore
American journal of ophthalmology, 2011, Vol.151 (4), p.671-681
18.
Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists
by Bahn, Rebecca S.
Thyroid (New York, N.Y.), 2011-06-01, Vol.21 (6), p.593-646
19.
Perioperative β blockers in patients having non-cardiac surgery: a meta-analysis
by Bangalore, Sripal, MD
The Lancet (British edition), 2008, Vol.372 (9654), p.1962-1976
20.
Early β-blocker use and in-hospital mortality in patients with Takotsubo cardiomyopathy
by Isogai, Toshiaki
Heart (British Cardiac Society), 2016-07, Vol.102 (13), p.1029-1035
